Bioavailability of low-dose oral etoposide

K. R. Hande, M. G. Krozely, F. A. Greco, J. D. Hainsworth, D. H. Johnson

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Purpose: To determine the bioavailability of oral etoposide capsules administered at doses of 100 mg and 400 mg. Patients and Methods: The bioavailability of oral etoposide was determined by measuring the area under the etoposide plasma concentration versus time curve (AUC) following intravenous (IV) etoposide administration and comparing that value to the AUC achieved following an oral dose administered 1 day later to the same patient. The bioavailability of a 100-mg oral dose of etoposide was measured on 16 occasions in 11 patients. The bioavailability of a 400-mg dose was determined on 12 occasions in six patients. Results: The mean (± SD) bioavailability following a 100-mg dose of oral etoposide was 76% ± 22%, which was significantly greater (P < .01) than the mean bioavailability of 48% ± 18% following a 400-mg oral dose. The coefficient of variation in oral etoposide bioavailability was significant: 29% with a 100-mg oral dose and 37% with a 400-mg dose. Conclusion: Bioavailability of a 100-mg oral etoposide dose is greater than suggested in the package insert from Bristol Laboratories (Evansville, IN). Comparable oral etoposide doses are not uniformly twice that of an IV dose, as suggested by the package insert, but will depend on the final oral dose administered. Bioavailability is better at lower oral etoposide doses. This study confirms the wide interpatient and intrapatient variability in oral etoposide bioavailability.

Original languageEnglish (US)
Pages (from-to)374-377
Number of pages4
JournalJournal of Clinical Oncology
Volume11
Issue number2
StatePublished - 1993

Fingerprint

Etoposide
Biological Availability
Product Labeling
Area Under Curve
Intravenous Administration
Capsules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hande, K. R., Krozely, M. G., Greco, F. A., Hainsworth, J. D., & Johnson, D. H. (1993). Bioavailability of low-dose oral etoposide. Journal of Clinical Oncology, 11(2), 374-377.

Bioavailability of low-dose oral etoposide. / Hande, K. R.; Krozely, M. G.; Greco, F. A.; Hainsworth, J. D.; Johnson, D. H.

In: Journal of Clinical Oncology, Vol. 11, No. 2, 1993, p. 374-377.

Research output: Contribution to journalArticle

Hande, KR, Krozely, MG, Greco, FA, Hainsworth, JD & Johnson, DH 1993, 'Bioavailability of low-dose oral etoposide', Journal of Clinical Oncology, vol. 11, no. 2, pp. 374-377.
Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH. Bioavailability of low-dose oral etoposide. Journal of Clinical Oncology. 1993;11(2):374-377.
Hande, K. R. ; Krozely, M. G. ; Greco, F. A. ; Hainsworth, J. D. ; Johnson, D. H. / Bioavailability of low-dose oral etoposide. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 2. pp. 374-377.
@article{01a98d1296af46f89d284c696563208e,
title = "Bioavailability of low-dose oral etoposide",
abstract = "Purpose: To determine the bioavailability of oral etoposide capsules administered at doses of 100 mg and 400 mg. Patients and Methods: The bioavailability of oral etoposide was determined by measuring the area under the etoposide plasma concentration versus time curve (AUC) following intravenous (IV) etoposide administration and comparing that value to the AUC achieved following an oral dose administered 1 day later to the same patient. The bioavailability of a 100-mg oral dose of etoposide was measured on 16 occasions in 11 patients. The bioavailability of a 400-mg dose was determined on 12 occasions in six patients. Results: The mean (± SD) bioavailability following a 100-mg dose of oral etoposide was 76{\%} ± 22{\%}, which was significantly greater (P < .01) than the mean bioavailability of 48{\%} ± 18{\%} following a 400-mg oral dose. The coefficient of variation in oral etoposide bioavailability was significant: 29{\%} with a 100-mg oral dose and 37{\%} with a 400-mg dose. Conclusion: Bioavailability of a 100-mg oral etoposide dose is greater than suggested in the package insert from Bristol Laboratories (Evansville, IN). Comparable oral etoposide doses are not uniformly twice that of an IV dose, as suggested by the package insert, but will depend on the final oral dose administered. Bioavailability is better at lower oral etoposide doses. This study confirms the wide interpatient and intrapatient variability in oral etoposide bioavailability.",
author = "Hande, {K. R.} and Krozely, {M. G.} and Greco, {F. A.} and Hainsworth, {J. D.} and Johnson, {D. H.}",
year = "1993",
language = "English (US)",
volume = "11",
pages = "374--377",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Bioavailability of low-dose oral etoposide

AU - Hande, K. R.

AU - Krozely, M. G.

AU - Greco, F. A.

AU - Hainsworth, J. D.

AU - Johnson, D. H.

PY - 1993

Y1 - 1993

N2 - Purpose: To determine the bioavailability of oral etoposide capsules administered at doses of 100 mg and 400 mg. Patients and Methods: The bioavailability of oral etoposide was determined by measuring the area under the etoposide plasma concentration versus time curve (AUC) following intravenous (IV) etoposide administration and comparing that value to the AUC achieved following an oral dose administered 1 day later to the same patient. The bioavailability of a 100-mg oral dose of etoposide was measured on 16 occasions in 11 patients. The bioavailability of a 400-mg dose was determined on 12 occasions in six patients. Results: The mean (± SD) bioavailability following a 100-mg dose of oral etoposide was 76% ± 22%, which was significantly greater (P < .01) than the mean bioavailability of 48% ± 18% following a 400-mg oral dose. The coefficient of variation in oral etoposide bioavailability was significant: 29% with a 100-mg oral dose and 37% with a 400-mg dose. Conclusion: Bioavailability of a 100-mg oral etoposide dose is greater than suggested in the package insert from Bristol Laboratories (Evansville, IN). Comparable oral etoposide doses are not uniformly twice that of an IV dose, as suggested by the package insert, but will depend on the final oral dose administered. Bioavailability is better at lower oral etoposide doses. This study confirms the wide interpatient and intrapatient variability in oral etoposide bioavailability.

AB - Purpose: To determine the bioavailability of oral etoposide capsules administered at doses of 100 mg and 400 mg. Patients and Methods: The bioavailability of oral etoposide was determined by measuring the area under the etoposide plasma concentration versus time curve (AUC) following intravenous (IV) etoposide administration and comparing that value to the AUC achieved following an oral dose administered 1 day later to the same patient. The bioavailability of a 100-mg oral dose of etoposide was measured on 16 occasions in 11 patients. The bioavailability of a 400-mg dose was determined on 12 occasions in six patients. Results: The mean (± SD) bioavailability following a 100-mg dose of oral etoposide was 76% ± 22%, which was significantly greater (P < .01) than the mean bioavailability of 48% ± 18% following a 400-mg oral dose. The coefficient of variation in oral etoposide bioavailability was significant: 29% with a 100-mg oral dose and 37% with a 400-mg dose. Conclusion: Bioavailability of a 100-mg oral etoposide dose is greater than suggested in the package insert from Bristol Laboratories (Evansville, IN). Comparable oral etoposide doses are not uniformly twice that of an IV dose, as suggested by the package insert, but will depend on the final oral dose administered. Bioavailability is better at lower oral etoposide doses. This study confirms the wide interpatient and intrapatient variability in oral etoposide bioavailability.

UR - http://www.scopus.com/inward/record.url?scp=0027537102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027537102&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 374

EP - 377

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -